Mannitol

Identification

Summary

Mannitol is a sugar alcohol used to test for asthma, to reduce intracranial and intraocular pressure, to measure glomerular filtration rate, and to manage pulmonary symptoms associated with cystic fibrosis.

Brand Names
Aridol, Bronchitol, Cystosol, Osmitrol, Sag-M
Generic Name
Mannitol
DrugBank Accession Number
DB00742
Background

Mannitol is an osmotic diuretic that is metabolically inert in humans and occurs naturally, as a sugar or sugar alcohol, in fruits and vegetables. Mannitol elevates blood plasma osmolality, resulting in enhanced flow of water from tissues, including the brain and cerebrospinal fluid, into interstitial fluid and plasma. As a result, cerebral edema, elevated intracranial pressure, and cerebrospinal fluid volume and pressure may be reduced. Mannitol may also be used for the promotion of diuresis before irreversible renal failure becomes established; the promotion of urinary excretion of toxic substances; as an Antiglaucoma agent; and as a renal function diagnostic aid.

On October 30, 2020, mannitol was approved by the FDA as add-on maintenance therapy for the control of pulmonary symptoms associated with cystic fibrosis in adult patients and is currently marketed for this indication under the name BRONCHITOL® by Chiesi USA Inc.8

Type
Small Molecule
Groups
Approved, Investigational
Structure
Weight
Average: 182.1718
Monoisotopic: 182.07903818
Chemical Formula
C6H14O6
Synonyms
  • (2R,3R,4R,5R)-hexane-1,2,3,4,5,6-hexaol
  • (2R,3R,4R,5R)-hexane-1,2,3,4,5,6-hexol
  • D-(-)-Mannitol
  • D-Mannitol
  • Manitol
  • Manna Sugar
  • Mannit
  • Mannite
  • Mannitol
  • Mannitolum
External IDs
  • E 421
  • E-421
  • INS NO.421
  • INS-421

Pharmacology

Indication

Used for the promotion of diuresis before irreversible renal failure becomes established, the reduction of intracranial pressure, the treatment of cerebral edema, and the promotion of urinary excretion of toxic substances.

Mannitol is also indicated as add-on maintenance therapy for improving pulmonary function in cystic fibrosis patients aged 18 and over who have passed the BRONCHITOL tolerance test (BTT). It is recommended that patients take an orally inhaled short-acting bronchodilator 5-15 minutes prior to every inhaled mannitol dose.8

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Treatment ofAcute renal failure••••••••••••
Treatment ofCerebral edema••••••••••••
Adjunct therapy in maintenance ofCystic fibrosis (cf)•••••••••••••••••• ••• •••••••••• ••••••••• •••• •••••••••••
Management ofIncreased intraocular pressure••••••••••••
Associated Therapies
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Chemically, mannitol is an alcohol and a sugar, or a polyol; it is similar to xylitol or sorbitol. However, mannitol has a tendency to lose a hydrogen ion in aqueous solutions, which causes the solution to become acidic. For this reason, it is not uncommon to add a substance to adjust its pH, such as sodium bicarbonate. Mannitol is commonly used to increase urine production (diuretic). It is also used to treat or prevent medical conditions that are caused by an increase in body fluids/water (e.g., cerebral edema, glaucoma, kidney failure). Mannitol is frequently given along with other diuretics (e.g., furosemide, chlorothiazide) and/or IV fluid replacement.

Inhaled mannitol has the possibility to cause bronchospasm and hemoptysis; the occurrence of either should lead to discontinuation of inhaled mannitol.8

Mechanism of action

Mannitol is an osmotic diuretic that is metabolically inert in humans and occurs naturally, as a sugar or sugar alcohol, in fruits and vegetables. Mannitol elevates blood plasma osmolality, resulting in enhanced flow of water from tissues, including the brain and cerebrospinal fluid, into interstitial fluid and plasma. As a result, cerebral edema, elevated intracranial pressure, and cerebrospinal fluid volume and pressure may be reduced. As a diurectic mannitol induces diuresis because it is not reabsorbed in the renal tubule, thereby increasing the osmolality of the glomerular filtrate, facilitating excretion of water, and inhibiting the renal tubular reabsorption of sodium, chloride, and other solutes. Mannitol promotes the urinary excretion of toxic materials and protects against nephrotoxicity by preventing the concentration of toxic substances in the tubular fluid. As an Antiglaucoma agent mannitol levates blood plasma osmolarity, resulting in enhanced flow of water from the eye into plasma and a consequent reduction in intraocular pressure. As a renal function diagnostic aid mannitol is freely filtered by the glomeruli with less than 10% tubular reabsorption. Therefore, its urinary excretion rate may serve as a measurement of glomerular filtration rate (GFR).

The exact mechanism of action of inhaled mannitol in the symptomatic maintenance treatment of cystic fibrosis remains unclear.7,8 It is hypothesized that mannitol produces an osmotic gradient across the airway epithelium that draws fluid into the extracellular space and alters the properties of the airway surface mucus layer, allowing easier mucociliary clearance.7

Absorption

Approximately 7% of ingested mannitol is absorbed during gastrointestinal perfusion in uremic patients.

Inhalation of 635 mg of mannitol powder yields a plasma Cmax of 13.71 μg/mL in 1.5 hours (Tmax) and a mean systemic AUC of 73.15 μg*h/mL.8

Volume of distribution

Mannitol administered intravenously has a volume of distribution of 34.3 L.8

Protein binding

Not Available

Metabolism

Mannitol is metabolized only slightly, if at all, to glycogen in the liver.

Hover over products below to view reaction partners

Route of elimination

Mannitol is primarily excreted unchanged in the urine. Following oral inhalation of 635 mg of mannitol in healthy volunteers, 55% of the total dose was recovered unchanged in the urine; following oral or intravenous administration of 500 mg, the corresponding values were 54 and 87%, respectively.8

Half-life

Mannitol has an elimination half-life of 4.7 hours following oral administration; the mean terminal elimination half-life is similar regardless of administration route (oral, inhalation, and intravenous.8

Clearance

Intravenous administration of mannitol yields a total clearance of 5.1 L/hr and renal clearance of 4.4 L/hr.8

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Mannitol overdose may result in bronchoconstriction and should be counteracted using a short-acting bronchodilator and other symptomatic and supportive care, as necessary.8

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbacavirMannitol may increase the excretion rate of Abacavir which could result in a lower serum level and potentially a reduction in efficacy.
AbaloparatideThe risk or severity of adverse effects can be increased when Mannitol is combined with Abaloparatide.
AbemaciclibThe serum concentration of Abemaciclib can be increased when it is combined with Mannitol.
AbrocitinibThe serum concentration of Mannitol can be increased when it is combined with Abrocitinib.
AcebutololThe risk or severity of adverse effects can be increased when Mannitol is combined with Acebutolol.
Food Interactions
No interactions found.

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
International/Other Brands
Anol (Astar) / Aridol (Pharmaxis) / Deltamannit (DeltaSelect) / Demanitol (Medifarma) / Diurecide (Lusa) / Isotol / Manicol / Manit (Pliva) / Manitol Mein (Fresenius) / Maniton / Mannigen / Mannisol (Human Co. Ltd.) / Mannisol A (Teva) / Mannit / Mannit-Lösung (Serag-Wiessner) / Mannite Actipharm (Actipharm) / Osmofundin (B. Braun) / Osmohale (Pharmaxis) / Osmosol (Beximco) / Osmosteril (Fresenius) / Resectisol (B. Braun)
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
BronchitolCapsule40 mgRespiratory (inhalation)Pharmaxis Europe Limited2016-09-08Not applicableEU flag
BronchitolCapsule40 mgRespiratory (inhalation)Pharmaxis Europe Limited2016-09-08Not applicableEU flag
BronchitolCapsule40 mg/1Respiratory (inhalation)Chiesi USA, Inc.2021-02-012025-09-30US flag
MannitolInjection, solution12.5 g/50mLIntravenousGeneral Injectables & Vaccines, Inc2019-11-192023-12-01US flag
MannitolInjection, solution20 g/100mLIntravenousHospira, Inc.2005-09-192021-12-08US flag
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
MannitolInjection, solution250 mg/1mLIntravenousFresenius Kabi USA, LLC2000-03-19Not applicableUS flag
MannitolInjection, solution250 mg/1mLIntravenousAMERICAN REGENT, INC.1990-09-302012-06-07US flag
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Curestem Cell Healer C20Powder0.06 g/2mLTopicalDNK CORPORATION LTD.2020-06-05Not applicableUS flag
GD11 Rx SCM C5Liquid0.10 g/2mLTopicalCoson Co., Ltd.2017-07-01Not applicableUS flag
MANNITOL 20% INTRAVENOUS INJECTION 500MLInjection20 %IntravenousPOLYLAB BIOTECH SDN. BHD.2013-05-312019-05-10Malaysia flag
MANNITOL INTRAVENOUS INJECTION 20%Injection20 g/100mlIntravenousJOYSON PTE. LTD.1998-10-29Not applicableSingapore flag
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
Additive Solution Sodium Adenine Glucose Mannitol (sagm)Mannitol (5.25 g) + Adenine (0.169 g) + Dextrose, unspecified form (9 g) + Sodium chloride (8.77 g)SolutionExtracorporealMaco Pharma2016-08-22Not applicableCanada flag
Adsol Red Cell PreservationMannitol (825 mg/110mL) + Adenine (30 mg/110mL) + Citric acid (209 mg/70mL) + D-glucose monohydrate (1.78 g/70mL) + D-glucose monohydrate (2.42 g/110mL) + Sodium chloride (990 mg/110mL) + Sodium citrate dihydrate (1.84 g/70mL) + Sodium phosphate, monobasic, monohydrate (155 mg/70mL)KitIntravenousFenwal, Inc.2017-02-28Not applicableUS flag
Adsol Red Cell PreservationMannitol (825 mg/110mL) + Adenine (30 mg/110mL) + Citric acid (209 mg/70mL) + D-glucose monohydrate (1.78 g/70mL) + D-glucose monohydrate (2.42 g/110mL) + Sodium chloride (990 mg/110mL) + Sodium citrate dihydrate (1.84 g/70mL) + Sodium phosphate, monobasic, monohydrate (155 mg/70mL)KitIntravenousFenwal, Inc.2017-02-28Not applicableUS flag
Adsol Red Cell PreservationMannitol (825 mg/110mL) + Adenine (30 mg/110mL) + Citric acid (209 mg/70mL) + D-glucose monohydrate (1.78 g/70mL) + D-glucose monohydrate (2.42 g/110mL) + Sodium chloride (990 mg/110mL) + Sodium citrate dihydrate (1.84 g/70mL) + Sodium phosphate, monobasic, monohydrate (155 mg/70mL)Kit; SolutionIntravenousFenwal, Inc.2021-12-09Not applicableUS flag
Adsol Red Cell PreservationMannitol (825 mg/110mL) + Adenine (30 mg/110mL) + Citric acid (209 mg/70mL) + D-glucose monohydrate (1.78 g/70mL) + D-glucose monohydrate (2.42 g/110mL) + Sodium chloride (990 mg/110mL) + Sodium citrate dihydrate (1.84 g/70mL) + Sodium phosphate, monobasic, monohydrate (155 mg/70mL)Kit; SolutionIntravenousFenwal, Inc.2021-12-09Not applicableUS flag
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
%20 MANNITOL SUDAKI SOLUSYON 1000 ML (CAM SISE) SETLIMannitol (20 %)SolutionIntravenousPOLİFARMA İLAÇ SAN. VE TİC. A.Ş.2020-08-14Not applicableTurkey flag
%20 MANNITOL SUDAKI SOLUSYON 1000 ML (CAM SISE) SETSIZMannitol (20 %)SolutionIntravenousPOLİFARMA İLAÇ SAN. VE TİC. A.Ş.2020-08-14Not applicableTurkey flag
%20 MANNITOL SUDAKI SOLUSYON 500 ML (CAM SISE) SETLIMannitol (20 %)SolutionIntravenousPOLİFARMA İLAÇ SAN. VE TİC. A.Ş.2020-08-14Not applicableTurkey flag
%20 MANNITOL SUDAKI SOLUSYON 500 ML (CAM SISE) SETSIZMannitol (20 %)SolutionIntravenousPOLİFARMA İLAÇ SAN. VE TİC. A.Ş.2020-08-14Not applicableTurkey flag
Curestem Cell Healer C10 ProgramMannitol (0.06 g/2mL) + Panthenol (0.25 g/5mL)KitTopicalDNK CORPORATION LTD.2020-06-05Not applicableUS flag

Categories

ATC Codes
B05CX04 — MannitolA06AD16 — MannitolR05CB16 — MannitolB05BC01 — MannitolV04CX04 — Mannitol
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as sugar alcohols. These are hydrogenated forms of carbohydrate in which the carbonyl group (aldehyde or ketone, reducing sugar) has been reduced to a primary or secondary hydroxyl group.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Carbohydrates and carbohydrate conjugates
Direct Parent
Sugar alcohols
Alternative Parents
Monosaccharides / Secondary alcohols / Polyols / Primary alcohols / Hydrocarbon derivatives
Substituents
Alcohol / Aliphatic acyclic compound / Hydrocarbon derivative / Monosaccharide / Polyol / Primary alcohol / Secondary alcohol / Sugar alcohol
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
mannitol (CHEBI:16899)
Affected organisms
  • Humans and other mammals

Chemical Identifiers

UNII
3OWL53L36A
CAS number
69-65-8
InChI Key
FBPFZTCFMRRESA-KVTDHHQDSA-N
InChI
InChI=1S/C6H14O6/c7-1-3(9)5(11)6(12)4(10)2-8/h3-12H,1-2H2/t3-,4-,5-,6-/m1/s1
IUPAC Name
(2R,3R,4R,5R)-hexane-1,2,3,4,5,6-hexol
SMILES
OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO

References

Synthesis Reference

Walter M. Kruse, "Process for preparing mannitol from glucose." U.S. Patent US4029878, issued August, 1956.

US4029878
General References
  1. Cruz J, Minoja G, Okuchi K: Improving clinical outcomes from acute subdural hematomas with the emergency preoperative administration of high doses of mannitol: a randomized trial. Neurosurgery. 2001 Oct;49(4):864-71. [Article]
  2. Cruz J, Minoja G, Okuchi K: Major clinical and physiological benefits of early high doses of mannitol for intraparenchymal temporal lobe hemorrhages with abnormal pupillary widening: a randomized trial. Neurosurgery. 2002 Sep;51(3):628-37; discussion 637-8. [Article]
  3. Cruz J, Minoja G, Okuchi K, Facco E: Successful use of the new high-dose mannitol treatment in patients with Glasgow Coma Scale scores of 3 and bilateral abnormal pupillary widening: a randomized trial. J Neurosurg. 2004 Mar;100(3):376-83. [Article]
  4. Roberts I, Smith R, Evans S: Doubts over head injury studies. BMJ. 2007 Feb 24;334(7590):392-4. [Article]
  5. Wakai A, Roberts I, Schierhout G: Mannitol for acute traumatic brain injury. Cochrane Database Syst Rev. 2005 Oct 19;(4):CD001049. [Article]
  6. Wang YM, van Eys J: Nutritional significance of fructose and sugar alcohols. Annu Rev Nutr. 1981;1:437-75. [Article]
  7. Southern KW, Clancy JP, Ranganathan S: Aerosolized agents for airway clearance in cystic fibrosis. Pediatr Pulmonol. 2019 Jun;54(6):858-864. doi: 10.1002/ppul.24306. Epub 2019 Mar 18. [Article]
  8. FDA Approved Drug Products: BRONCHITOL (mannitol) oral inhalation powder [Link]
Human Metabolome Database
HMDB0000765
KEGG Drug
D00062
KEGG Compound
C00392
PubChem Compound
6251
PubChem Substance
46506446
ChemSpider
6015
BindingDB
50142798
RxNav
6628
ChEBI
16899
ChEMBL
CHEMBL689
ZINC
ZINC000002041302
Therapeutic Targets Database
DAP000874
PharmGKB
PA450320
PDBe Ligand
MTL
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Mannitol
PDB Entries
1m2w / 1p6k / 1rs6 / 1rs7 / 1zzq / 1zzu / 2vfu / 3n62 / 3n65 / 3n66
show 7 more
FDA label
Download (50 KB)
MSDS
Download (72.1 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedNot AvailableBowel preparation therapy1
4CompletedNot AvailableBrain Swelling1
4CompletedDiagnosticAsthma1
4CompletedDiagnosticFood Allergy1
4CompletedDiagnosticUreteral Patency1

Pharmacoeconomics

Manufacturers
  • B braun medical inc
  • Hospira inc
  • Miles laboratories inc
  • Abraxis pharmaceutical products
  • App pharmaceuticals llc
  • Astrazeneca lp
  • International medication system
  • Luitpold pharmaceuticals inc
  • Merck and co inc
  • Watson laboratories inc
  • Baxter healthcare corp
Packagers
  • American Regent
  • APP Pharmaceuticals
  • B. Braun Melsungen AG
  • Baxter International Inc.
  • Hospira Inc.
  • Luitpold Pharmaceuticals Inc.
  • Mallinckrodt Inc.
  • Organon Pharmaceuticals
Dosage Forms
FormRouteStrength
SolutionIntravenous10 %
SolutionIntravenous20 %
SolutionIntravenous5 %
SolutionExtracorporeal
Kit; solutionIntravenous
SolutionIntravenous
KitRespiratory (inhalation)
Kit; powderRespiratory (inhalation)
Solution20 %
SolutionIntravenous
CapsuleRespiratory (inhalation)40 mg/1
CapsuleRespiratory (inhalation)40 mg
Powder, meteredRespiratory (inhalation)40 MG
KitIntravenous
PowderTopical0.06 g/2mL
KitTopical
LiquidIrrigation
SolutionIntravenous20.0 g
LiquidTopical0.10 g/2mL
InjectionIntravenous
Injection, solutionParenteral20 %
SolutionIntravenous100 g
Solution, concentrateIntravenous20 g
InjectionParenteral15 %
Injection, solutionIntravenous10 g/100mL
Injection, solutionIntravenous12.5 g/50mL
Injection, solutionIntravenous15 g/100mL
Injection, solutionIntravenous20 g/100mL
Injection, solutionIntravenous250 mg/1mL
Injection, solutionIntravenous5 g/100mL
IrrigantIrrigation5 g/100mL
Injection, solutionIntravenous20 %
InjectionIntravenous20 %
LiquidIntravenous100 mg / mL
LiquidIntravenous250 mg / mL
LiquidIntravenous50 mg / mL
SolutionIntravenous25 %
InjectionIntravenous20 g/100ml
Injection, solutionParenteral10 %
Injection, solutionParenteral18 %
Injection, solutionParenteral5 %
Injection, solutionIntravenous
Injection, solutionIntravenous10 %
Injection, solutionIntravenous18 %
Injection, solutionIntravenous5 %
Injection, solutionParenteral
SolutionIrrigation5 %
SolutionExtracorporeal; Intrabiliary; Intracardiac
InjectionIntravenous17.5 g/100ml
SolutionParenteral20.000 g
SolutionIntravenous20 g
CreamTopical
LiquidIrrigation5 %
SolutionIrrigation5 g/100ml
SolutionUnknown
InjectionParenteral20 g
SolutionIrrigation
IrrigantUrethral
Prices
Unit descriptionCostUnit
Osmitrol 20% iv solution0.15USD ml
Osmitrol 10% iv solution0.07USD ml
Osmitrol 15% iv solution0.07USD ml
Mannitol powder0.05USD g
Mannitol 15% iv solution0.04USD ml
Mannitol 20% iv solution0.04USD ml
Mannitol 25% vial0.03USD ml
Osmitrol 5% iv solution0.03USD ml
Mannitol 10% iv solution0.02USD ml
Mannitol 5% iv solution0.02USD ml
Resectisol 5% solution0.01USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)168 °CPhysProp
boiling point (°C)290-295 °C at 3.50E+00 mm HgPhysProp
water solubility2.16E+005 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP-3.10HANSCH,C ET AL. (1995)
Caco2 permeability-6.21ADME Research, USCD
pKa13.5 (at 25 °C)BUDAVARI,S ET AL. (1996)
Predicted Properties
PropertyValueSource
Water Solubility229.0 mg/mLALOGPS
logP-2.7ALOGPS
logP-3.7Chemaxon
logS0.1ALOGPS
pKa (Strongest Acidic)12.59Chemaxon
pKa (Strongest Basic)-3Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count6Chemaxon
Hydrogen Donor Count6Chemaxon
Polar Surface Area121.38 Å2Chemaxon
Rotatable Bond Count5Chemaxon
Refractivity38.4 m3·mol-1Chemaxon
Polarizability17.04 Å3Chemaxon
Number of Rings0Chemaxon
Bioavailability1Chemaxon
Rule of FiveNoChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+0.6525
Blood Brain Barrier-0.5997
Caco-2 permeable-0.8958
P-glycoprotein substrateNon-substrate0.662
P-glycoprotein inhibitor INon-inhibitor0.9535
P-glycoprotein inhibitor IINon-inhibitor0.9551
Renal organic cation transporterNon-inhibitor0.9252
CYP450 2C9 substrateNon-substrate0.8706
CYP450 2D6 substrateNon-substrate0.878
CYP450 3A4 substrateNon-substrate0.7431
CYP450 1A2 substrateNon-inhibitor0.824
CYP450 2C9 inhibitorNon-inhibitor0.9419
CYP450 2D6 inhibitorNon-inhibitor0.9412
CYP450 2C19 inhibitorNon-inhibitor0.9232
CYP450 3A4 inhibitorNon-inhibitor0.9402
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.958
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.7823
BiodegradationReady biodegradable0.8595
Rat acute toxicity1.1260 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9709
hERG inhibition (predictor II)Non-inhibitor0.9329
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (9.14 KB)
Spectra
SpectrumSpectrum TypeSplash Key
GC-MS Spectrum - GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies) (6 TMS)GC-MSsplash10-0ktb-0931000000-b481d576c5f24dd1b1d5
GC-MS Spectrum - GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies)GC-MSsplash10-066s-0942000000-20043a375d72ca08dce9
GC-MS Spectrum - GC-MS (6 TMS)GC-MSsplash10-066r-1974000000-38a4beaca17ab8c750b6
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSsplash10-03k9-9500000000-97c5853d3e9b96f9d054
GC-MS Spectrum - EI-BGC-MSsplash10-0229-9100000000-5655e9df8e0fdcaa72a0
GC-MS Spectrum - EI-BGC-MSsplash10-001i-9200000000-0dad802ab0000303cb33
GC-MS Spectrum - GC-EI-TOFGC-MSsplash10-0ktb-0931000000-b481d576c5f24dd1b1d5
GC-MS Spectrum - GC-EI-TOFGC-MSsplash10-066s-0942000000-20043a375d72ca08dce9
GC-MS Spectrum - GC-MSGC-MSsplash10-066r-1974000000-38a4beaca17ab8c750b6
GC-MS Spectrum - GC-EI-TOFGC-MSsplash10-066s-0942000000-f4df881aeebac32de5c7
MS/MS Spectrum - Quattro_QQQ 10V, Positive (Annotated)LC-MS/MSsplash10-014j-9600000000-26f4335f7ef7c81ca261
MS/MS Spectrum - Quattro_QQQ 25V, Positive (Annotated)LC-MS/MSsplash10-066r-9000000000-73db1fbd51fb8c061bec
MS/MS Spectrum - Quattro_QQQ 40V, Positive (Annotated)LC-MS/MSsplash10-05mo-9000000000-45a4dea1d21286c4b8da
LC-MS/MS Spectrum - LC-ESI-QTOF (UPLC Q-Tof Premier, Waters) , NegativeLC-MS/MSsplash10-0089-6900000000-961d76d6550bc342ffa1
LC-MS/MS Spectrum - LC-ESI-QTOF , negativeLC-MS/MSsplash10-0089-6900000000-061f88989a6ac71321e3
MS/MS Spectrum - Linear Ion Trap , negativeLC-MS/MSsplash10-0ik9-1900000000-eb8ea056f3b1dfe2fb1f
MS/MS Spectrum - Linear Ion Trap , negativeLC-MS/MSsplash10-03di-1900000000-6768b4744e1a4e56b18b
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00kb-1900000000-0765563624accf132d03
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-00dr-0900000000-e159f4e76b7847313f35
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-0900-0910000000-8d56394cbc78dd3b5ca0
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-0079-0900000000-63517bff4abfbf09e1ca
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-0w2l-0940000000-dc20c851073dcbc4dba9
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-0002-1900000000-4ab672652f75cad56155
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-0fk9-9400000000-4cd13edeb09c142d341a
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-01ox-9000000000-f19f32df289cd4120aa7
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0a4i-9000000000-ab60612ad89757b77d6f
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0007-9000000000-ff50dc2ad9d92f2d15c4
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0a4i-9000000000-bcb06a092689afa069a6
1H NMR Spectrum1D NMRNot Applicable
1H NMR Spectrum1D NMRNot Applicable
13C NMR Spectrum1D NMRNot Applicable
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
[1H,13C] 2D NMR Spectrum2D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-141.0000088
predicted
DarkChem Lite v0.1.0
[M-H]-141.0375088
predicted
DarkChem Lite v0.1.0
[M-H]-140.4352088
predicted
DarkChem Lite v0.1.0
[M-H]-140.7223088
predicted
DarkChem Lite v0.1.0
[M-H]-141.4147088
predicted
DarkChem Lite v0.1.0
[M-H]-143.92418
predicted
DeepCCS 1.0 (2019)
[M+H]+140.8955088
predicted
DarkChem Lite v0.1.0
[M+H]+140.3376088
predicted
DarkChem Lite v0.1.0
[M+H]+141.5336088
predicted
DarkChem Lite v0.1.0
[M+H]+140.7346088
predicted
DarkChem Lite v0.1.0
[M+H]+143.1315088
predicted
DarkChem Lite v0.1.0
[M+H]+146.31975
predicted
DeepCCS 1.0 (2019)
[M+Na]+140.6177088
predicted
DarkChem Lite v0.1.0
[M+Na]+142.322217
predicted
DarkChem Standard v0.1.0
[M+Na]+140.2490088
predicted
DarkChem Lite v0.1.0
[M+Na]+140.9211088
predicted
DarkChem Lite v0.1.0
[M+Na]+140.9555088
predicted
DarkChem Lite v0.1.0
[M+Na]+152.23225
predicted
DeepCCS 1.0 (2019)

Enzymes

Kind
Protein
Organism
Pseudomonas fluorescens
Pharmacological action
Unknown
Actions
Substrate
General Function
Nucleotide binding
Specific Function
Not Available
Gene Name
mtlD
Uniprot ID
O08355
Uniprot Name
Mannitol dehydrogenase
Molecular Weight
54497.41 Da
References
  1. Wang YM, van Eys J: Nutritional significance of fructose and sugar alcohols. Annu Rev Nutr. 1981;1:437-75. [Article]

Drug created at June 13, 2005 13:24 / Updated at March 18, 2024 16:48